Accuray (NASDAQ:ARAY) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Wednesday, December 25th, BidAskClub reports.
ARAY traded down $0.15 during trading hours on Wednesday, reaching $3.28. The company’s stock had a trading volume of 821,973 shares, compared to its average volume of 560,540. Accuray has a fifty-two week low of $2.35 and a fifty-two week high of $5.40. The stock has a market cap of $301.81 million, a PE ratio of -21.87 and a beta of 1.98. The business’s 50-day moving average is $2.83 and its 200-day moving average is $3.03. The company has a debt-to-equity ratio of 5.22, a current ratio of 1.94 and a quick ratio of 1.20.
Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, October 29th. The medical equipment provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Accuray had a negative net margin of 4.02% and a negative return on equity of 35.92%. The business had revenue of $89.58 million during the quarter, compared to analyst estimates of $93.34 million. Analysts expect that Accuray will post -0.14 EPS for the current year.
In other Accuray news, CEO Joshua Levine sold 17,587 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $2.88, for a total transaction of $50,650.56. Also, CFO Shigeyuki Hamamatsu sold 10,563 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $2.70, for a total value of $28,520.10. Following the transaction, the chief financial officer now owns 185,644 shares in the company, valued at $501,238.80. The disclosure for this sale can be found here. Insiders have sold 62,663 shares of company stock worth $169,767 over the last 90 days. 3.30% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System raised its stake in shares of Accuray by 7.0% in the third quarter. California Public Employees Retirement System now owns 68,131 shares of the medical equipment provider’s stock valued at $189,000 after acquiring an additional 4,477 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Accuray by 376.1% in the second quarter. Royal Bank of Canada now owns 6,547 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 5,172 shares in the last quarter. Swiss National Bank raised its stake in shares of Accuray by 3.6% in the second quarter. Swiss National Bank now owns 163,600 shares of the medical equipment provider’s stock valued at $633,000 after acquiring an additional 5,700 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Accuray by 5.1% in the third quarter. California State Teachers Retirement System now owns 140,588 shares of the medical equipment provider’s stock valued at $389,000 after acquiring an additional 6,831 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Accuray by 18.5% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 53,054 shares of the medical equipment provider’s stock valued at $205,000 after acquiring an additional 8,300 shares in the last quarter. Institutional investors own 76.93% of the company’s stock.
About Accuray
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.